Skip to main content

Table 1 Effect of CCl4 on the liver injury

From: Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease

 

Control group No CCl4

CCl4 administration groups

Recovery groups CCl4 withdrawal

  

6 weeks

8 weeks

12 weeks

1 week

2 weeks

Collagen (%)

0.22 (0.04)

0.97 (0.31)a

0.47 (0.06)a

3.6 (0.3)a, e, h

0.67 (0.09)a

0.73 (0.16)a

α-smooth muscle actin staining (%)

0.109 (0.02)

1.2 (0.3)b

0.41 (0.07)b

1.8 (0.5)b, g

0.21 (0.03)a, d

0.11 (0.02)d, i

Aspartate aminotransferase (μkat/L)

2.0 (0.2)

5.9 (1.2)a

5.4 (1.0)a

25.0 (7.7)a, c, f

2.3 (0.4)d

2.0 (0.3)d

Cholesterol (mmol/L)

0.94 (0.07)

0.70 (0.09)a

0.78 (0.15)

1.08 (0.14)c

1.00 (0.15)

1.12 (0.95)

Triglycerides (mmol/L)

2.65 (0.41)

0.63 (0.08)b

0.56 (0.06)b

0.72 (0.18)b

1.08 (0.13)b

0.89 (0.13)b

  1. a: p ≤ 0.05, b: p < 0.01, with respect to the control group. c: p ≤ 0.05, d: p < 0.01, e: p < 0.001, with respect to 6 weeks of CCl4 administration. f: p ≤ 0.05, g: p < 0.01, h: p < 0.001, with respect to 8 weeks of CCl4 administration. i: p ≤ 0.05, with respect to 1 week of CCl4 withdrawal/recovery